In a turf war with Eli Lil­ly, No­vo Nordisk steps off with pos­i­tive PhI­II for its chal­leng­ing oral GLP-1 drug

Just a cou­ple of months af­ter No­vo Nordisk shook up the big di­a­betes mar­ket with the ar­rival of its GLP-1 drug Ozem­pic (semaglu­tide) in the US, the big Dan­ish com­pa­ny has be­gun rolling out the first in a long line­up of Phase III stud­ies for its next-gen oral ver­sion of the drug. And the de­but of the Phase III da­ta start­ed out on a pos­i­tive note.

Re­searchers for No­vo say that the first of 10 Phase III stud­ies that read out this year came with sta­tis­ti­cal­ly sig­nif­i­cant re­sults on all three dos­es test­ed. And if they can stay on track, they plan to field the first ever oral GLP-1 to reg­u­la­tors in 2019, vow­ing to com­mand an even big­ger share of the mega block­buster mar­ket af­ter over­com­ing some huge hur­dles in de­vel­op­ing an oral pep­tide ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.